Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.47 |
| ▸ | HTR6 | P50406 | 4/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24390568 | 0.81 | PDE10A (0.48) | PDE10APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13354930 | 0.78 | CYP1A2 (0.56) | SMN1; SMN2TOP2A | |
| SCHEMBL25936308 | 0.77 | TOP2A (0.58) | KDM4ESMN1; SMN2HTR6TOP2AFEN1 | |
| SCHEMBL3515107 | 0.76 | FEN1 (0.53) | KDM4ESMN1; SMN2PDE10AFEN1 | |
| SCHEMBL4274948 | 0.75 | HTR6 (0.53) | KDM4ESMN1; SMN2HTR6 | |
| SCHEMBL11562270 | 0.73 | KDM4E (0.49) | KDM4ESMN1; SMN2HTR6TOP2APDE4A | |
| SCHEMBL4267456 | 0.73 | HTR6 (0.54) | KDM4ESMN1; SMN2HTR6 | |
| SCHEMBL4269092 | 0.73 | HTR6 (0.44) | KDM4ESMN1; SMN2HTR6 | |
| SCHEMBL4278723 | 0.73 | HTR6 (0.54) | KDM4ESMN1; SMN2HTR6 | |
| SCHEMBL4277542 | 0.72 | KDM4E (0.54) | KDM4ESMN1; SMN2PDE10AHTR6PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608717-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080070943-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-03-20 | — | — | US | disclosed |
| US-7291736-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070943-A1 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | KDM4E 2278/4885SMN1; SMN2 562/4885PDE10A 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.